These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1719049)

  • 21. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma.
    Henrique R; Azevedo R; Bento MJ; Domingues JC; Silva C; Jerónimo C
    J Am Acad Dermatol; 2000 Dec; 43(6):991-1000. PubMed ID: 11100014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
    Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
    Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of proliferation and motility in primary malignant melanoma of the skin.
    Smolle J; Hofmann-Wellenhof R; Kerl H
    J Cutan Pathol; 1992 Apr; 19(2):110-5. PubMed ID: 1597566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading.
    Kaudewitz P; Braun-Falco O; Ernst M; Landthaler M; Stolz W; Gerdes J
    Am J Pathol; 1989 May; 134(5):1063-8. PubMed ID: 2719076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma.
    Laprie C; Abadie J; Amardeilh MF; Net JL; Lagadic M; Delverdier M
    Vet Dermatol; 2001 Jun; 12(3):139-47. PubMed ID: 11420929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear size and shape parameters correlate with proliferative activity in cutaneous melanocytic tumors.
    Smolle J; Hofmann-Wellenhof R; Soyer HP; Stettner H; Kerl H
    J Invest Dermatol; 1989 Jul; 93(1):178-82. PubMed ID: 2746003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skin.
    Korabiowska M; Brinck U; Hoenig JF; Bartkowski SB; Mirecka J; Schauer A
    J Cancer Res Clin Oncol; 1994; 120(6):365-8. PubMed ID: 8138562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Method of melanin bleaching in MIB1-Ki67 immunostaining of pigmented lesions: A quantitative evaluation in malignant melanomas.
    Li LX; Crotty KA; Kril JJ; Palmer AA; McCarthy SW
    Histochem J; 1999 Apr; 31(4):237-40. PubMed ID: 10447065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical characteristics of melanoma.
    Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
    J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions.
    Tran TA; Ross JS; Carlson JA; Mihm MC
    Hum Pathol; 1998 Oct; 29(10):1085-90. PubMed ID: 9781646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Ki-67 antigen in primary human melanomas--its relationship to mitotic rate and tumor thickness and its stability.
    Ostmeier H; Suter L
    Arch Dermatol Res; 1989; 281(3):173-7. PubMed ID: 2774644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of biomarkers in malignant melanoma.
    Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
    Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions.
    Moretti S; Massobrio R; Brogelli L; Novelli M; Giannotti B; Bernengo MG
    J Invest Dermatol; 1990 Sep; 95(3):320-4. PubMed ID: 1696603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Ki-67 expression in feline non-ocular melanocytic tumours.
    Sabattini S; Renzi A; Albanese F; Fantinati M; Rigillo A; Abramo F; Tornago R; Tortorella G; Massaro M; Pagano TB; Buchholz J; Bettini G
    BMC Vet Res; 2018 Oct; 14(1):309. PubMed ID: 30314485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
    Takahashi H; Strutton GM; Parsons PG
    Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.
    Niezabitowski A; Czajecki K; Ryś J; Kruczak A; Gruchała A; Wasilewska A; Lackowska B; Sokołowski A; Szklarski W
    J Surg Oncol; 1999 Mar; 70(3):150-60. PubMed ID: 10102344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
    Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Franssila K; Collan Y; Pyrhönen S
    Oncology; 1999 Oct; 57(3):242-52. PubMed ID: 10545794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.
    Talve L; Sauroja I; Collan Y; Punnonen K; Ekfors T
    Int J Cancer; 1997 Jun; 74(3):255-9. PubMed ID: 9221801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.